Ricefidase

N/A

Report date: 2025/04/27 17:19:18

Base Information

Drug NameRicefidase
Drug Alias NameRecombinant IgG Cleaving EnzymeKJ-103KJ103
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionImmunoglobulin G degraders
TargetsImmunoglobulin G
Therapy Area/IndicationsRejection of renal transplantationGuillain-Barre SyndromeAnti-Glomerular Basement Membrane Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Bao Pharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Bao Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationGuillain-Barre SyndromeAnti-Glomerular Basement Membrane Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A